Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants.

Omar SI, Tuszynski J.

Oncotarget. 2018 Dec 14;9(98):37137-37156. doi: 10.18632/oncotarget.26440. eCollection 2018 Dec 14.

2.

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.

Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J.

Cell Death Dis. 2018 May 1;9(5):439. doi: 10.1038/s41419-018-0463-7.

3.

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.

Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG.

Front Oncol. 2016 Feb 3;6:21. doi: 10.3389/fonc.2016.00021. eCollection 2016. Review.

4.

Dynamics and Molecular Mechanisms of p53 Transcriptional Activation.

Offutt TL, Ieong PU, Demir Ö, Amaro RE.

Biochemistry. 2018 Nov 20;57(46):6528-6537. doi: 10.1021/acs.biochem.8b01005. Epub 2018 Nov 12.

PMID:
30388364
5.

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.

Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U, Wiman KG.

Cell Death Dis. 2015 Jun 18;6:e1794. doi: 10.1038/cddis.2015.143.

6.

Plakoglobin restores tumor suppressor activity of p53R175H mutant by sequestering the oncogenic potential of β-catenin.

Alaee M, Nool K, Pasdar M.

Cancer Sci. 2018 Jun;109(6):1876-1888. doi: 10.1111/cas.13612. Epub 2018 May 23.

7.

Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.

Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z.

J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30.

PMID:
18996393
8.

Virtual screening using covalent docking to find activators for G245S mutant p53.

Omar SI, Lepre MG, Morbiducci U, Deriu MA, Tuszynski JA.

PLoS One. 2018 Sep 7;13(9):e0200769. doi: 10.1371/journal.pone.0200769. eCollection 2018.

9.

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53.

Wassman CD, Baronio R, Demir Ö, Wallentine BD, Chen CK, Hall LV, Salehi F, Lin DW, Chung BP, Hatfield GW, Richard Chamberlin A, Luecke H, Lathrop RH, Kaiser P, Amaro RE.

Nat Commun. 2013;4:1407. doi: 10.1038/ncomms2361.

10.

Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism.

Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN, Carpizo DR.

Oncotarget. 2014 Oct 15;5(19):8879-92.

11.

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246.

Haffo L, Lu J, Bykov VJN, Martin SS, Ren X, Coppo L, Wiman KG, Holmgren A.

Sci Rep. 2018 Aug 23;8(1):12671. doi: 10.1038/s41598-018-31048-7.

12.

Functional interplay between MDM2, p63/p73 and mutant p53.

Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dötsch V, Vousden KH.

Oncogene. 2015 Aug 13;34(33):4300-10. doi: 10.1038/onc.2014.359. Epub 2014 Nov 24.

13.

An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53.

Malami I, Muhammad A, Etti IC, Waziri PM, Alhassan AM.

EXCLI J. 2017 Dec 8;16:1276-1287. doi: 10.17179/excli2017-299. eCollection 2017.

14.

Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.

Sankala H, Vaughan C, Wang J, Deb S, Graves PR.

Arch Biochem Biophys. 2011 Aug 1;512(1):52-60. doi: 10.1016/j.abb.2011.05.005. Epub 2011 May 20.

15.

A common gain of function of p53 cancer mutants in inducing genetic instability.

Liu DP, Song H, Xu Y.

Oncogene. 2010 Feb 18;29(7):949-56. doi: 10.1038/onc.2009.376. Epub 2009 Nov 2.

16.

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.

Wiman KG.

Oncogene. 2010 Jul 29;29(30):4245-52. doi: 10.1038/onc.2010.188. Epub 2010 May 24. Review.

PMID:
20498645
17.

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).

Tan BS, Tiong KH, Choo HL, Chung FF, Hii LW, Tan SH, Yap IK, Pani S, Khor NT, Wong SF, Rosli R, Cheong SK, Leong CO.

Cell Death Dis. 2015 Jul 16;6:e1826. doi: 10.1038/cddis.2015.191.

18.

MPK-09, a small molecule inspired from bioactive styryllactone restores the wild-type function of mutant p53.

Metri PK, Naz S, Kondaiah P, Prasad KR.

ACS Chem Biol. 2013 Jul 19;8(7):1429-34. doi: 10.1021/cb3005929. Epub 2013 Apr 26.

PMID:
23621494
19.

ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation.

Morton DJ, Patel D, Joshi J, Hunt A, Knowell AE, Chaudhary J.

Oncotarget. 2017 Jan 10;8(2):2536-2549. doi: 10.18632/oncotarget.13701.

20.

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.

Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, Mueller SC, Agostino SD, Blandino G, Avantaggiati ML, Chung FL.

Cell Death Differ. 2016 Oct;23(10):1615-27. doi: 10.1038/cdd.2016.48. Epub 2016 Jun 3.

Supplemental Content

Support Center